title: Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
abstract: Inotuzumab ozogamicin is a humanized anti-CD22 monoclonal antibody bound to a toxic natural calicheamicin, which is under investigation for the treatment of relapsed/refractory acute lymphoblastic leukemia. CD22 is commonly expressed in 90-100% of malignant mature B-lymphocyte lineage. The first Phase II study with inotuzumab ozogamicin conducted by Kantarjian et al. gave the opportunity for heavily pretreated patients with acute lymphoblastic leukemia to go for allogeneic stem cell transplant. Inotuzumab is well-tolerated with the exception of veno-occlusive disease. Overall inotuzumab ozogamicin is potentially an encouraging and promising therapy for patients.
authors.affiliation: Department of Leukemia, MD Anderson Cancer Centre, Houston, TX 77030, USA.
authors.forename: Binsah
authors.initials: B
authors.lastname: George
authors.affiliation: Department of Leukemia, MD Anderson Cancer Centre, Houston, TX 77030, USA.
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.affiliation: Department of Leukemia, MD Anderson Cancer Centre, Houston, TX 77030, USA.
authors.forename: Elias
authors.initials: E
authors.lastname: Jabbour
authors.affiliation: Department of Leukemia, MD Anderson Cancer Centre, Houston, TX 77030, USA.
authors.forename: Nitin
authors.initials: N
authors.lastname: Jain
mesh_terms: D064591:Allografts; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D000080045:Inotuzumab Ozogamicin; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*; D033581:Stem Cell Transplantation
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000080045:Inotuzumab Ozogamicin
keywords: acute lymphoblastic leukemia; antibody drug conjugate; inotuzumab; monoclonal antibody